RegMed XB
RegMed XB is a Dutch-Flemish public-private consortium that accelerates regenerative medicine from research to clinic via five Moonshot programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis), the Pilot Factory infrastructure, and a 60+ partner ecosystem across academia, health foundations, industry, and government.
- Company typePrivate
- Founded2017
- HeadquartersMaastricht, Netherlands
- Headcount101–250
- GTM typeB2B
- OfferingServices
What RegMed XB does
RegMed XB is a Dutch-Flemish public-private research consortium (operating as Stichting REGenerative MEDicine crossing Borders in the Netherlands and RegMed XB Flanders vzw in Belgium) that accelerates the translation of regenerative medicine from academic research into clinical application. The organization runs five focused Moonshot research programs targeting Cardiovascular regeneration, Type 1 Diabetes cure, Eye (corneal) restoration, Kidney disease (including bioengineered subunits and a wearable artificial kidney now in first-in-human trials), and Osteoarthritis (bio-artificial joints), spanning cell therapy, gene therapy, tissue engineering, organoid technology, biofabrication/3D bioprinting, and biomaterial implants within the ATMP category.
The consortium is anchored by the RegMed XB Pilot Factory, described as one of the largest international regenerative medicine infrastructures, which provides scale-up and de-risking capacity for portfolio projects. It is supported by an ecosystem of more than 60 partners across health foundations (Dutch Heart Foundation, Kidney Foundation, Diabetes Fonds, Oogfonds, ReumaNederland, Dutch Brain Foundation), 11+ academic institutions (LUMC, UMC Utrecht, KU Leuven, TU/e, Maastricht University/MERLN), 30+ industrial partners (including Mimetas for organ-on-chip), and 7 government bodies (Health Holland, RVO, National Growth Fund, and the Ministries of EZK, OCW, and VWS).
RegMed XB does not sell commercial products; instead its revenue mechanics comprise government grants and public funding, seed capital deployment through the FIRST fund (co-managed with Biogeneration Ventures), Valorization Vouchers and business development services, and partner contributions. The value proposition for its stakeholders is the de-risking of promising concepts from academia through proof-of-concept and early clinical stages before commercial partners take them forward, with the organization monetizing principally through program execution, technology transfer, and convening rather than direct product sales.
RegMed XB firmographics
Firmographics- Name
- RegMed XB
- Legal name
- Stichting REGenerative MEDicine crossing Borders
- Website
- https://regmedxb.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- RegMed XB is a Dutch-Flemish public-private consortium that accelerates regenerative medicine from research to clinic via five Moonshot programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis), the Pilot Factory infrastructure, and a 60+ partner ecosystem across academia, health foundations, industry, and government.
- Ownership category
- akta.pro rank
RegMed XB industry classification
Industry- Product category
- Regenerative Medicine Research and ATMP Infrastructure
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industry
- Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)
Keywords
Where RegMed XB is headquartered
LocationHeadquarters
- HQ city
- Maastricht
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
RegMed XB business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Others
Revenue model
- Government Grants and Public Funding: RegMed XB receives support from national and local governments including Health Holland, Ministry of EZK, Ministry of OCW, Ministry of VWS, Netherlands Enterprise Agency (RVO), and National Growth Fund (NGF) to de-risk promising concepts from academia to proof of concept or initial clinical trial stages before commercial partners take over.
- Seed Capital and Investment Fund Management: Manages seed capital programs including the FIRST fund (jointly with BGV) for early-stage investment in regenerative and cardiovascular medicine. Receives funding from Thematic Tech Transfer (TTT) program and SRGO subsidy scheme.
- Valorization Services: Provides Valorization Vouchers and business development support to help innovators accelerate, de-risk, and scale regenerative therapies. Revenue generated through service fees and successful technology transfer/valorization of research outcomes.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
RegMed XB product offering
Product offeringCore offering
RegMed XB runs multi-year regenerative medicine research programs (five Moonshots covering cardiovascular, Type 1 diabetes, eye, kidney, and osteoarthritis indications) and provides shared Pilot Factory infrastructure that researchers and companies use to scale and de-risk Advanced Therapy Medicinal Products (ATMPs). It supplements these with valorization services (business development, Valorization Vouchers) and the FIRST seed capital fund co-managed with Biogeneration Ventures, functioning as a public-private translation platform rather than a product vendor.
Product overview
RegMed XB is a Dutch-Flemish research consortium (Stichting REGenerative MEDicine crossing Borders and RegMed XB Flanders vzw) operating as a platform organization that accelerates regenerative medicine through five interconnected offerings: (1) Five Moonshot research excellence programs (Cardiovascular, Diabetes, Eye, Kidney, Osteoarthritis) targeting specific chronic diseases through advanced therapy medicinal products; (2) The Pilot Factory, a large-scale infrastructure facility enabling researchers and companies to scale and de-risk regenerative therapies toward market; (3) Valorization services including Valorization Vouchers and business development support; (4) Seed capital through the FIRST fund for early-stage companies; and (5) An annual conference serving as a community platform for the regenerative medicine ecosystem. The organization functions as a public-private partnership connecting academic institutions, health foundations, industrial partners, and governmental agencies.
Differentiator
Problem solved
Functional benefit
Products and services
- Pilot Factory (regenerative medicine infrastructure)
- Valorization Team Services
- Seed Capital & FIRST Fund
Quantifiable outcome
- Growing 100 nephrons per organoid with scalability to 50,000 nephrons in large organoid sheets (Kidney Moonshot)
- +4 more outcomes
Companies that use RegMed XB
Customer profileSegments5 records
Ideal customer profiles4 records
RegMed XB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
RegMed XB partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered core and major.
- InsermcoreOn July 2, 2025, RegMed XB and Inserm (French National Institute of Health and Medical Research) signed a Memorandum of Understanding to strengthen scientific collaboration in biomedical research. The signing was hosted by the French Ambassador to the Netherlands at the French Residence in The Hague.
- Nakanoshima QrosscoreRegMed XB and Nakanoshima Qross (International Hub for Future Medicine based in Osaka, Japan) signed a memorandum of understanding to promote cooperation in regenerative medicine. Nakanoshima Qross delegation visited in October 2025 to strengthen ties.
- Dutch Heart Foundation (Hartstichting)coreHealth foundation involved in defining research objectives and providing guidance in research to ensure focus on patients. Co-governs the Cardiovascular Moonshot.
- Dutch Kidney Foundation (Nierstichting)coreHealth foundation driving the Kidney Moonshot, defining research objectives and co-governing the program. Supports first-in-human clinical trials for wearable artificial kidney.
- Diabetes FondscoreHealth foundation focused on Type 1 diabetes research, co-governing the Diabetes Moonshot and supporting Cure One research center at LUMC.
- Stichting DONcoreFoundation with goal to cure Type 1 diabetes, investing nationally and internationally in fundamental and clinical research for a cure.
- OogfondscoreHealth foundation focused on preventing eye diseases and supporting people with visual impairments, co-governing the Eye Moonshot.
- ReumaNederlandcoreHealth foundation for rheumatism patients (2+ million people), co-governing the Osteoarthritis Moonshot focused on bio-artificial joint development.
- HersenstichtingcoreDutch Brain Foundation supporting brain-related research within the RegMed XB ecosystem.
- Health HollandcoreGovernmental partner providing funding and support for Life Sciences & Health innovation in the Netherlands.
- Dutch Cardiovascular Alliance (DCVA)coreStrategic partnership for cardiovascular research collaboration, joint valorization activities, and community events.
- ATMP XBcore€3.5 million Interreg-cofunded initiative led by Biovia to reinforce cross-border ecosystem for ATMPs in Flanders and South Netherlands. RegMed XB is a proud contributor.
- MimetasmajorIndustrial partner specializing in organ-on-a-chip technology, collaborating with Kidney Moonshot for kidney research and development.
- KU LeuvencoreTop-rated academic institution contributing researchers and expertise to multiple Moonshots. Home to Prometheus platform for Skeletal Tissue Engineering.
- LUMCcoreLeiden University Medical Center leading Diabetes Moonshot and hosting Cure One research center for Type 1 diabetes cure research.
- UMC UtrechtcoreUniversity Medical Center leading Kidney Moonshot (with Prof. Marianne Verhaar) and Cardiovascular Moonshot research activities.
- TU/e (Eindhoven University of Technology)coreAcademic partner contributing expertise in biomedical engineering, biomaterials, and biofabrication for Osteoarthritis and Kidney Moonshots.
- Maastricht University / MUMC+coreAcademic partner hosting MERLN Institute for Technology-Inspired Regenerative Medicine, contributing to multiple Moonshots including Diabetes and Osteoarthritis.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
RegMed XB competitors and assessment
Company assessmentEmerging players
- Aspect Biosystems: Canadian biotech developing 3D bioprinted tissue therapeutics with focus on metabolic disease and ophthalmology. Directly comparable on biofabrication and tissue engineering technology overlap with RegMed XB's Osteoarthritis and Eye Moonshots.
- Mesoblast: Australia-headquartered clinical-stage cell therapy company developing mesenchymal lineage cell therapies for inflammatory and cardiovascular diseases. Overlaps with RegMed XB's Cardiovascular Moonshot in regenerative approaches to heart failure.
- Vericel Corporation: US commercial-stage cell therapy company marketing MACI (autologous chondrocyte implant for cartilage repair) and Epicel. Directly comparable on cartilage regeneration with overlap to RegMed XB's Osteoarthritis Moonshot.
Broad incumbents
- Lonza Cell & Gene Technologies: Swiss-headquartered global contract development and manufacturing organization (CDMO) with the largest cell and gene therapy manufacturing footprint. Relevant as the leading ATMP manufacturing partner/infrastructure provider that RegMed XB's Pilot Factory competes with or routes work to.
- Organogenesis: US-headquartered commercial regenerative medicine company marketing wound care and surgical biologics products. Comparable as a commercial-stage player in regenerative medicine with overlapping musculoskeletal and tissue engineering focus.
Direct peers
- California Institute for Regenerative Medicine (CIRM): California state-funded agency created by voter proposition that funds stem cell and regenerative medicine research across academic and commercial entities. Operates a comparable model of public funding flowing through a coordinating consortium to advance regenerative therapies.
- Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW): International stem cell research consortium with nodes in Denmark, the Netherlands, and Australia, funded by the Novo Nordisk Foundation. Directly comparable as a multi-institutional regenerative medicine research consortium with significant long-term foundation backing.
- Centre for Commercialization of Regenerative Medicine (CCRM): Canadian regenerative medicine consortium that operates a similar public-private model with academic-industry partnerships, pilot manufacturing facilities, and venture creation to commercialize cell and gene therapies. Directly comparable in structure and mission to RegMed XB.
- Cell and Gene Therapy Catapult: UK-based non-profit consortium accelerating cell and gene therapy commercialization through shared infrastructure, skills development, and clinical trial support. Closely analogous to RegMed XB's consortium-driven ATMP acceleration model across the UK ecosystem.
Regional players
- Ncardia: Belgium-headquartered stem cell technology company developing iPSC-derived cardiac and neural cell models and manufacturing services. Comparable as a Benelux-based stem cell specialist serving drug discovery and regenerative medicine applications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights1 record
Customer concentration
RegMed XB social profiles
Digital presenceRegMed XB compliance and trust
Trust signalCompliance1 record
RegMed XB financial estimates
Financial estimateRevenue estimate
Valuation estimate
RegMed XB leadership team
Management profileNumber of profiles
Profiles20 records
RegMed XB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RegMed XB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RegMed XB
What does RegMed XB do?
RegMed XB runs multi-year regenerative medicine research programs (five Moonshots covering cardiovascular, Type 1 diabetes, eye, kidney, and osteoarthritis indications) and provides shared Pilot Factory infrastructure that researchers and companies use to scale and de-risk Advanced Therapy Medicinal Products (ATMPs). It supplements these with valorization services (business development, Valorization Vouchers) and the FIRST seed capital fund co-managed with Biogeneration Ventures, functioning as a public-private translation platform rather than a product vendor.
Is RegMed XB a public or private company?
RegMed XB is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was RegMed XB founded?
RegMed XB was founded in 2017. It employs 101 to 250 people.
Where is RegMed XB based?
RegMed XB is headquartered in Maastricht, Netherlands, in the Europe region.
How does RegMed XB make money?
Three revenue lines are on record. Government Grants and Public Funding is the primary driver. The others are seed Capital and Investment Fund Management and valorization Services.
Who are RegMed XB's main competitors?
Emerging players on record are Aspect Biosystems, Mesoblast and Vericel Corporation. Broad incumbents are Lonza Cell & Gene Technologies and Organogenesis. Direct peers are California Institute for Regenerative Medicine (CIRM), Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Centre for Commercialization of Regenerative Medicine (CCRM) and Cell and Gene Therapy Catapult. Ncardia is listed as a regional player.
Does RegMed XB have an API?
No public API is recorded for RegMed XB.
What industry is RegMed XB in?
RegMed XB's product category is Regenerative Medicine Research and ATMP Infrastructure. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAGAGAD, Cell Banking & Viral Seed Services (MCB/WCB/VSB). Its NAICS code is 541714 and its SIC code is 3842.